Iridex Comments on Changing Glaucoma Reimbursement Landscape
Portfolio Pulse from
Iridex Corporation announced that the new Local Coverage Determination (LCD) L37531 for Micro-Invasive Glaucoma Surgery (MIGS) has been adopted, potentially increasing the use of Iridex's laser-based treatments for glaucoma.
November 19, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Iridex Corporation announced the adoption of LCD L37531, which may increase the use of its laser-based glaucoma treatments due to reimbursement changes.
The adoption of LCD L37531 is expected to increase physician interest in Iridex's laser-based treatments for glaucoma, potentially boosting sales and positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100